RAPT Q1 2021 Earnings Report
Key Takeaways
RAPT Therapeutics reported a net loss of $16.5 million for the first quarter of 2021, compared to a net loss of $13.1 million for the first quarter of 2020. As of March 31, 2021, the Company had cash and cash equivalents and marketable securities of $98.4 million.
Net loss for the first quarter of 2021 was $16.5 million, compared to $13.1 million for the first quarter of 2020.
Research and development expenses for the first quarter of 2021 were $13.8 million, compared to $10.7 million for the same period in 2020.
General and administrative expenses for the first quarter of 2021 were $4.0 million, compared to $3.3 million for the same period of 2020.
As of March 31, 2021, the Company had cash and cash equivalents and marketable securities of $98.4 million.